GOGrainne M O'Kane

Grainne M O'Kane

*This is an algorithmically generated author record based on publicly available information.

Grainne M O'Kane has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Steven Gallinger

    Centre d’oncologie Princess Margaret (O’Kane, Gallinger), Réseau universitaire de santé de Toronto, Toronto, Ont.; Université de l’Alberta (Ladak), Edmonton, Alb

    3 shared publications
  • Farah Ladak

    Centre d’oncologie Princess Margaret (O’Kane, Gallinger), Réseau universitaire de santé de Toronto, Toronto, Ont.; Université de l’Alberta (Ladak), Edmonton, Alb

    2 shared publications
  • Amy Zhang

    PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research

    1 shared publication
  • Anna Dodd

    Department of Medial Oncology and Hematology, Princess Margaret Cancer Centre

    1 shared publication
  • Barbara Grunwald

    Department of Urology, West German Cancer Center, University Hospital Essen, Essen, Germany

    1 shared publication
  • Bernard Lam

    Adaptive Oncology, Ontario Institute for Cancer Research

    1 shared publication

Latest Publications

  • Open Access

    Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique

    by Grainne M. O’kane, Farah Ladak, Steven Gallinger


  • Open Access

    Advances in the management of pancreatic ductal adenocarcinoma

    by Grainne M. O’kAne, Farah Ladak, Steven Gallinger


  • Open Access

    Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review

    by Flora Jung, Keegan Guidolin, Michael Ho-Yan Lee, Kimberley Lam-Tin-Cheung, Grace Zhao, Sachin Doshi, Tyler Chesney, Marina Englesakis, Jelena Lukovic, Grainne O’kane, et al.

    While adjuvant treatment of colon cancers that penetrate the serosa (T4) have been well-established, neoadjuvant strategies have yet to be formally evaluated. Our objective was to perform a scoping review of eligibility criteria, treatment regimens, and primary outcomes for neoadjuvant approaches to T4 colon cancer. A librarian-led, systematic search of MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL up to 11 February 2020 was performed. Primary research evaluating neoadjuvant treatment in T4 colon cancer were included. Screening and data abstraction were performed in duplicate; analyses were descriptive or thematic. A total of twenty studies were included, most of which were single-arm, single-center, and retrospective. The primary objectives of the literature to date has been to evaluate treatment feasibility, tumor response, disease-free survival, and overall survival in healthy patients. Conventional XELOX and FOLFOX chemotherapy were the most commonly administered interventions. Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. The current literature on neoadjuvant strategies for T4 colon cancer is overrepresented by single-center, retrospective studies that evaluate treatment feasibility and efficacy in healthy patients. Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease.


  • Top Cited Papers

    GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

    by Grainne M O'Kane, Barbara T Grünwald, Gun-Ho Jang, Mehdi Masoomian, Sarah Picardo, Robert C Grant, Robert E Denroche, Amy Zhang, Yifan Wang, Bernard Lam, et al.

    Purpose: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker. Experimental design: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing. Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) were explored. Results: Between December 2015-May 2019, 195 patients (95%) had enough tissue for RNA sequencing; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% vs. 33% respectively (p=0.02). In patients with basal-like tumours treated with modified FOLFIRINOX (mFFX) (n=22) the progression rate was 60% compared to 15% in classical PDAC (p= 0.0002). Median OS in the intention to treat population (n=195) was 9.3 months for classical vs. 5.9 months for basal-like PDAC (HR 0.47 95% CI 0.32-0.69, p=0.0001). GATA6 expression by RNAseq highly correlated with the classifier (p<0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariable analysis, GATA6 expression was prognostic (p=0.02). In exploratory analyses, basal-like tumours, could be identified by keratin 5, were more hypoxic and enriched for a T cell inflamed gene expression signature. Conclusions :The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression.